BioSpace News Archive

Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.

The $80 million infusions from ATP will advance Marengo’s lead candidate, STAR0602, which aims to treat advanced and metastatic solid tumors.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the preclinical result of IBI319 was published in Nature Communications.

HUTCHMED Limited announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be presented at the upcoming 63rd American Society for Hematology’s Annual Meeting and Exposition, taking place on December 11-14, 2021.

CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, announced that its board directors resolved to increase the share repurchase program by up to HK$100 million.

Ascletis Pharma Inc. and Suzhou Alphamab Co., Ltd. jointly announce that Ascletis’ subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement outside Greater China for ASC22 to treat all viral diseases including Hepatitis B. ASC22, also known as KN035, is a first-in-class subcutaneously injected PD-L1 antibody.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen, will be presented at the American College of Asthma, Allergy & Immunology Annual Scientific Meeting in New Orleans and via livestream, November 4-8.